MACKENZIE WOLFE: Open Payments
NPI 1770296345 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$671 in 36 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $671
Food & beverage: $671
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $285 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $156 |
| E.R. Squibb & Sons, L.L.C. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Luye Pharma (USA) Ltd. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Tris Pharma Inc | 1 | $19 |
| Neurocrine BioSciences, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
Products named: VRAYLAR, CAPLYTA, COBENFY, FANAPT, ERZOFRI EXTENDED-RELEASE, Auvelity, Qelbree, Dyanavel XR.
Industry payments across NV — which companies pay providers there.
